Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium

Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the associati...

Full description

Saved in:
Bibliographic Details
Published inBMC medicine Vol. 14; no. 1; p. 62
Main Authors Ordóñez-Mena, José Manuel, Schöttker, Ben, Mons, Ute, Jenab, Mazda, Freisling, Heinz, Bueno-de-Mesquita, Bas, O’Doherty, Mark G., Scott, Angela, Kee, Frank, Stricker, Bruno H., Hofman, Albert, de Keyser, Catherine E., Ruiter, Rikje, Söderberg, Stefan, Jousilahti, Pekka, Kuulasmaa, Kari, Freedman, Neal D., Wilsgaard, Tom, de Groot, Lisette CPGM, Kampman, Ellen, Håkansson, Niclas, Orsini, Nicola, Wolk, Alicja, Nilsson, Lena Maria, Tjønneland, Anne, Pająk, Andrzej, Malyutina, Sofia, Kubínová, Růžena, Tamosiunas, Abdonas, Bobak, Martin, Katsoulis, Michail, Orfanos, Philippos, Boffetta, Paolo, Trichopoulou, Antonia, Brenner, Hermann
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.04.2016
BioMed Central
Subjects
Online AccessGet full text
ISSN1741-7015
1741-7015
DOI10.1186/s12916-016-0607-5

Cover

Loading…
Abstract Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
AbstractList Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation. Keywords: Smoking Cancer Incidence Mortality Cohort Meta-analysis
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.BACKGROUNDSmoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality.This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.METHODSThis is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs.Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.RESULTSOverall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking.This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.CONCLUSIONSThis investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods: This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results: Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate advancement periods (RAPs) may enhance communication of smoking related risk to the general population. Thus, we estimated RAPs for the association of smoking exposure (smoking status, time since smoking cessation, smoking intensity, and duration) with total and site-specific (lung, breast, colorectal, prostate, gastric, head and neck, and pancreatic) cancer incidence and mortality. Methods : This is a meta-analysis of 19 population-based prospective cohort studies with individual participant data for 897,021 European and American adults. For each cohort we calculated hazard ratios (HRs) for the association of smoking exposure with cancer outcomes using Cox regression adjusted for a common set of the most important potential confounding variables. RAPs (in years) were calculated as the ratio of the logarithms of the HRs for a given smoking exposure variable and age. Meta-analyses were employed to summarize cohort-specific HRs and RAPs. Results : Overall, 140,205 subjects had a first incident cancer, and 53,164 died from cancer, during an average follow-up of 12 years. Current smoking advanced the overall risk of developing and dying from cancer by eight and ten years, respectively, compared with never smokers. The greatest advancements in cancer risk and mortality were seen for lung cancer and the least for breast cancer. Smoking cessation was statistically significantly associated with delays in the risk of cancer development and mortality compared with continued smoking. Conclusions: This investigation shows that smoking, even among older adults, considerably advances, and cessation delays, the risk of developing and dying from cancer. These findings may be helpful in more effectively communicating the harmful effects of smoking and the beneficial effect of smoking cessation.
ArticleNumber 62
Audience Academic
Author Nilsson, Lena Maria
Bueno-de-Mesquita, Bas
O’Doherty, Mark G.
Hofman, Albert
Ruiter, Rikje
Jousilahti, Pekka
Kampman, Ellen
Ordóñez-Mena, José Manuel
Malyutina, Sofia
Orfanos, Philippos
Katsoulis, Michail
Orsini, Nicola
Scott, Angela
Freisling, Heinz
Stricker, Bruno H.
Söderberg, Stefan
Schöttker, Ben
Trichopoulou, Antonia
Wilsgaard, Tom
de Groot, Lisette CPGM
Freedman, Neal D.
Kee, Frank
Tamosiunas, Abdonas
Håkansson, Niclas
Tjønneland, Anne
Jenab, Mazda
Kubínová, Růžena
Brenner, Hermann
Wolk, Alicja
de Keyser, Catherine E.
Boffetta, Paolo
Mons, Ute
Kuulasmaa, Kari
Pająk, Andrzej
Bobak, Martin
Author_xml – sequence: 1
  givenname: José Manuel
  surname: Ordóñez-Mena
  fullname: Ordóñez-Mena, José Manuel
– sequence: 2
  givenname: Ben
  surname: Schöttker
  fullname: Schöttker, Ben
– sequence: 3
  givenname: Ute
  surname: Mons
  fullname: Mons, Ute
– sequence: 4
  givenname: Mazda
  surname: Jenab
  fullname: Jenab, Mazda
– sequence: 5
  givenname: Heinz
  surname: Freisling
  fullname: Freisling, Heinz
– sequence: 6
  givenname: Bas
  surname: Bueno-de-Mesquita
  fullname: Bueno-de-Mesquita, Bas
– sequence: 7
  givenname: Mark G.
  surname: O’Doherty
  fullname: O’Doherty, Mark G.
– sequence: 8
  givenname: Angela
  surname: Scott
  fullname: Scott, Angela
– sequence: 9
  givenname: Frank
  surname: Kee
  fullname: Kee, Frank
– sequence: 10
  givenname: Bruno H.
  surname: Stricker
  fullname: Stricker, Bruno H.
– sequence: 11
  givenname: Albert
  surname: Hofman
  fullname: Hofman, Albert
– sequence: 12
  givenname: Catherine E.
  surname: de Keyser
  fullname: de Keyser, Catherine E.
– sequence: 13
  givenname: Rikje
  surname: Ruiter
  fullname: Ruiter, Rikje
– sequence: 14
  givenname: Stefan
  surname: Söderberg
  fullname: Söderberg, Stefan
– sequence: 15
  givenname: Pekka
  surname: Jousilahti
  fullname: Jousilahti, Pekka
– sequence: 16
  givenname: Kari
  surname: Kuulasmaa
  fullname: Kuulasmaa, Kari
– sequence: 17
  givenname: Neal D.
  surname: Freedman
  fullname: Freedman, Neal D.
– sequence: 18
  givenname: Tom
  surname: Wilsgaard
  fullname: Wilsgaard, Tom
– sequence: 19
  givenname: Lisette CPGM
  surname: de Groot
  fullname: de Groot, Lisette CPGM
– sequence: 20
  givenname: Ellen
  surname: Kampman
  fullname: Kampman, Ellen
– sequence: 21
  givenname: Niclas
  surname: Håkansson
  fullname: Håkansson, Niclas
– sequence: 22
  givenname: Nicola
  surname: Orsini
  fullname: Orsini, Nicola
– sequence: 23
  givenname: Alicja
  surname: Wolk
  fullname: Wolk, Alicja
– sequence: 24
  givenname: Lena Maria
  surname: Nilsson
  fullname: Nilsson, Lena Maria
– sequence: 25
  givenname: Anne
  surname: Tjønneland
  fullname: Tjønneland, Anne
– sequence: 26
  givenname: Andrzej
  surname: Pająk
  fullname: Pająk, Andrzej
– sequence: 27
  givenname: Sofia
  surname: Malyutina
  fullname: Malyutina, Sofia
– sequence: 28
  givenname: Růžena
  surname: Kubínová
  fullname: Kubínová, Růžena
– sequence: 29
  givenname: Abdonas
  surname: Tamosiunas
  fullname: Tamosiunas, Abdonas
– sequence: 30
  givenname: Martin
  surname: Bobak
  fullname: Bobak, Martin
– sequence: 31
  givenname: Michail
  surname: Katsoulis
  fullname: Katsoulis, Michail
– sequence: 32
  givenname: Philippos
  surname: Orfanos
  fullname: Orfanos, Philippos
– sequence: 33
  givenname: Paolo
  surname: Boffetta
  fullname: Boffetta, Paolo
– sequence: 34
  givenname: Antonia
  surname: Trichopoulou
  fullname: Trichopoulou, Antonia
– sequence: 35
  givenname: Hermann
  surname: Brenner
  fullname: Brenner, Hermann
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27044418$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120629$$DView record from Swedish Publication Index
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422330$$DView record from Swedish Publication Index
http://kipublications.ki.se/Default.aspx?queryparsed=id:133289525$$DView record from Swedish Publication Index
BookMark eNp9U91u0zAYjdAQ-4EH4AYsTUJckGHHTpzsAqkqgyFNIMTPreU6TvttiV1sZ9WeiNfEpiu0E0ORY-vknGP75PsOsz1jjc6ypwSfEFJXrz0pGlLlOI0K87x8kB0QzkjOMSn3ttb72aH3lxgXJefsUbZfcMwYI_VB9vPzKE2ADpQMYA2yHQoLjfxgr8DMc-m9VSCDbpGSRmmHHPgrtIKwQC7CSLbXCR-0CWipHdjWn6JBB5lLI_sbDz5ZgmnhGtpR9mgpXQAFy7gramWQqHN2QMourAt-s_30fPJxevYlwsZHHMbhcfawk73XT27no-zbu7Ov0_P84tP7D9PJRa44oSEvcS0lb2iNaVk2SmtdxmAwbqumoy2TBW9pNatnqqScFnXbzWilZ21d1AzXjWroUXa69l3JuTYxAm2EkU6BF1aC6GHmpLsRq9EJ06dpOc68KDHhBYvifC32Kx1xsXQwJHZS3kJXcaUjv8JNHfmv7uW_he8TYd1cjKNgRUEp_q_9X_owClLgqkh3ebPmR_KgWxX_kZP9jmz3i4GFmNtrweoCN2UVDZ6vDVT86wFiEtZJQTCmPL5plW7w8nYLZ3-M2gcxgFe676XRdvSCcN7ggrA6mR3foV7a0cUiSayGV5g2bIs1l70WYDobT6aSqZgwVrOywYRG1sk_WPFp9QCxaHQHEd8RvNgSLLTsw8Lbfkw173eJz7Yz-xPWpmMigW8ysd473QkF4XfvxCNAH3MRqTfFujcFTiOWoCijktxRbszv1_wCI1o9PA
CitedBy_id crossref_primary_10_1093_cid_ciy508
crossref_primary_10_1016_j_canep_2016_10_011
crossref_primary_10_2105_AJPH_2018_304649
crossref_primary_10_1158_1055_9965_EPI_18_1327
crossref_primary_10_3390_cancers15133422
crossref_primary_10_1002_ags3_12546
crossref_primary_10_1136_jim_2017_000413
crossref_primary_10_1016_j_pan_2017_07_001
crossref_primary_10_1111_add_15791
crossref_primary_10_1002_14651858_CD013229_pub2
crossref_primary_10_1136_bmjopen_2020_037637
crossref_primary_10_1002_sim_8458
crossref_primary_10_1016_j_eururo_2022_03_033
crossref_primary_10_1016_j_autrev_2020_102633
crossref_primary_10_1007_s40122_022_00462_1
crossref_primary_10_1016_j_pmedr_2019_100875
crossref_primary_10_1038_s41430_019_0481_2
crossref_primary_10_1002_cam4_3525
crossref_primary_10_3390_cancers11010062
crossref_primary_10_3390_ijerph19063493
crossref_primary_10_1002_14651858_CD002850_pub4
crossref_primary_10_1016_j_critrevonc_2024_104323
crossref_primary_10_3238_arztebl_2018_0571
crossref_primary_10_3389_fsurg_2019_00019
crossref_primary_10_1007_s12035_019_1591_5
crossref_primary_10_1158_1055_9965_EPI_16_0858
crossref_primary_10_1159_000530435
crossref_primary_10_1016_j_amepre_2022_07_001
crossref_primary_10_1016_j_bpg_2017_09_002
crossref_primary_10_1007_s44197_023_00144_x
crossref_primary_10_1055_a_2338_3716
crossref_primary_10_18632_oncotarget_23841
crossref_primary_10_1002_pros_24646
crossref_primary_10_1097_MD_0000000000032233
crossref_primary_10_1016_j_envres_2019_108636
crossref_primary_10_6004_jnccn_2020_7657
crossref_primary_10_3390_ijerph19074084
crossref_primary_10_1038_s41598_024_56634_w
crossref_primary_10_1016_j_bpg_2017_09_001
crossref_primary_10_1002_14651858_CD013229
crossref_primary_10_1002_iid3_70145
crossref_primary_10_1002_ijc_31846
crossref_primary_10_1186_s12889_019_6576_9
crossref_primary_10_1186_s12889_019_7641_0
crossref_primary_10_1186_s40959_021_00094_y
crossref_primary_10_3389_fonc_2022_956451
crossref_primary_10_3389_fimmu_2022_1050876
crossref_primary_10_1080_0284186X_2021_1919756
crossref_primary_10_1016_j_ypmed_2019_03_015
crossref_primary_10_1080_0952813X_2018_1552319
crossref_primary_10_3389_fpubh_2022_780538
crossref_primary_10_1177_0391560319846012
crossref_primary_10_1136_rmdopen_2022_002874
crossref_primary_10_7759_cureus_62826
crossref_primary_10_1097_CM9_0000000000001652
crossref_primary_10_3892_wasj_2023_186
crossref_primary_10_1111_ajag_12842
crossref_primary_10_1093_annonc_mdx761
crossref_primary_10_1001_jamanetworkopen_2023_54958
crossref_primary_10_15430_JCP_2020_25_1_13
crossref_primary_10_26442_00403660_2020_02_000485
crossref_primary_10_1002_cam4_4647
crossref_primary_10_3389_fonc_2024_1499384
crossref_primary_10_3389_fonc_2020_568939
crossref_primary_10_1055_a_2338_3533
crossref_primary_10_1186_s12916_022_02417_x
crossref_primary_10_3389_fonc_2021_766939
crossref_primary_10_3390_cancers14174117
crossref_primary_10_1373_jalm_2018_028613
crossref_primary_10_2188_jea_JE20220206
crossref_primary_10_1161_CIRCRESAHA_121_318051
crossref_primary_10_1016_j_euf_2018_02_007
crossref_primary_10_1016_j_ejca_2018_09_007
crossref_primary_10_3390_cancers12113320
crossref_primary_10_1136_thorax_2021_217862
crossref_primary_10_1097_MCG_0000000000000935
crossref_primary_10_1007_s10120_023_01459_1
crossref_primary_10_2147_JMDH_S479699
crossref_primary_10_1093_annonc_mdy275
crossref_primary_10_1016_j_medmic_2022_100055
crossref_primary_10_1002_cncr_34172
crossref_primary_10_7326_L20_0070
crossref_primary_10_1007_s10654_020_00640_5
crossref_primary_10_1186_s12885_020_07213_5
crossref_primary_10_4046_trd_2019_0011
crossref_primary_10_12677_ACM_2021_117420
crossref_primary_10_1016_j_prnil_2024_03_003
crossref_primary_10_1126_sciadv_abn3328
crossref_primary_10_4103_jgmh_jgmh_23_20
crossref_primary_10_5334_aogh_4572
crossref_primary_10_3390_ijerph20095740
crossref_primary_10_1186_s12931_023_02420_7
crossref_primary_10_1080_2162402X_2020_1848068
crossref_primary_10_1515_med_2024_0974
crossref_primary_10_13105_wjma_v11_i5_228
crossref_primary_10_7554_eLife_82608
crossref_primary_10_3389_fendo_2020_00066
crossref_primary_10_2196_48380
crossref_primary_10_1016_j_hoc_2023_07_005
crossref_primary_10_6004_jnccn_2019_7346
Cites_doi 10.1016/j.amepre.2015.04.004
10.2105/AJPH.2008.150508
10.1016/j.ypmed.2014.05.013
10.1007/s10654-014-9977-1
10.1038/sj.bjc.6606080
10.1001/jama.2008.839
10.1038/sj.bjc.6600596
10.1186/1742-7622-10-6
10.1186/1471-2482-13-S2-S14
10.1007/s00423-007-0266-2
10.1002/ijc.23033
10.1016/j.ejca.2013.08.014
10.1016/0197-2456(86)90046-2
10.1016/j.yrtph.2013.06.001
10.1136/bmj.c221
10.1002/sim.1186
10.1002/ijc.28508
10.1007/s10552-008-9132-y
10.3399/bjgp12X636236
10.1136/bmj.327.7417.745
10.1093/aje/kwv092
10.1186/1471-2407-12-385
10.1002/ijc.24191
10.1001/jama.2013.284692
10.1136/tobaccocontrol-2012-050572
10.1002/jrsm.12
10.1136/bmj.h1551
10.1093/annonc/mdt302
10.1590/S0102-311X2010001200002
10.1002/sim.3944
10.1158/1055-9965.EPI-09-0252
10.2147/CIA.S80506
10.1093/jnci/djt023
10.1093/aje/kwr265
10.1097/00001648-199305000-00006
10.1038/bjc.2012.520
10.1001/jama.2015.3656
10.1093/oxfordjournals.aje.a116237
ContentType Journal Article
Copyright COPYRIGHT 2016 BioMed Central Ltd.
Copyright BioMed Central 2016
info:eu-repo/semantics/openAccess
Ordóñez-Mena et al. 2016
Wageningen University & Research
Copyright_xml – notice: COPYRIGHT 2016 BioMed Central Ltd.
– notice: Copyright BioMed Central 2016
– notice: info:eu-repo/semantics/openAccess
– notice: Ordóñez-Mena et al. 2016
– notice: Wageningen University & Research
CorporateAuthor on behalf of the Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
CorporateAuthor_xml – name: on behalf of the Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
– name: Consortium on Health and Ageing: Network of Cohorts in Europe and the United States (CHANCES)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7U9
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
C1K
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
3HK
5PM
ADHXS
ADTPV
AOWAS
D8T
D93
ZZAVC
DF2
QVL
DOI 10.1186/s12916-016-0607-5
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
NORA - Norwegian Open Research Archives
PubMed Central (Full Participant titles)
SWEPUB Umeå universitet full text
SwePub
SwePub Articles
SWEPUB Freely available online
SWEPUB Umeå universitet
SwePub Articles full text
SWEPUB Uppsala universitet
NARCIS:Publications
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE

Publicly Available Content Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1741-7015
ExternalDocumentID oai_library_wur_nl_wurpubs_501724
oai_swepub_ki_se_506098
oai_DiVA_org_uu_422330
oai_DiVA_org_umu_120629
PMC4820956
10037_10368
4092425761
A448459013
27044418
10_1186_s12916_016_0607_5
Genre Research Support, Non-U.S. Gov't
Meta-Analysis
Journal Article
GeographicLocations Netherlands
United States--US
Europe
GeographicLocations_xml – name: Netherlands
– name: United States--US
– name: Europe
GrantInformation_xml – fundername: NIA NIH HHS
  grantid: R01 AG023522
– fundername: World Health Organization
  grantid: 001
– fundername: ;
  grantid: 242244
GroupedDBID ---
0R~
23N
2WC
4.4
53G
5GY
5VS
6J9
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHSBF
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EJD
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
MK0
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7QL
7U9
7XB
8FK
AZQEC
C1K
DWQXO
H94
K9.
M7N
PKEHL
PQEST
PQUKI
PRINS
7X8
-5E
-5G
-A0
-BR
2VQ
3HK
AAPBV
ABPTK
ACRMQ
ADINQ
AFGXO
C1A
C24
IPNFZ
N95
RIG
5PM
ADHXS
ADTPV
AOWAS
D8T
D93
ZZAVC
DF2
PUEGO
-
5E
5G
A0
ADACO
BBAFP
BR
LI0
O0-
QVL
ID FETCH-LOGICAL-c713t-508aa793803559ceee560700d69f3d4a27d36b8bc537328dfb36ebd8284089c93
IEDL.DBID M48
ISSN 1741-7015
IngestDate Tue Jan 05 18:09:31 EST 2021
Mon Sep 01 03:36:40 EDT 2025
Thu Aug 21 06:55:27 EDT 2025
Thu Aug 21 06:50:55 EDT 2025
Thu Aug 21 14:11:53 EDT 2025
Sat Apr 29 05:41:37 EDT 2023
Thu Jul 10 18:59:37 EDT 2025
Sat Jul 26 02:28:47 EDT 2025
Tue Jun 17 22:07:49 EDT 2025
Tue Jun 10 21:05:47 EDT 2025
Thu May 22 21:24:07 EDT 2025
Mon Jul 21 05:51:15 EDT 2025
Thu Apr 24 22:53:29 EDT 2025
Tue Jul 01 01:14:47 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cohort
Mortality
Cancer
Incidence
Meta-analysis
Smoking
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c713t-508aa793803559ceee560700d69f3d4a27d36b8bc537328dfb36ebd8284089c93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
BMC Medicine
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12916-016-0607-5
PMID 27044418
PQID 1797603946
PQPubID 42775
ParticipantIDs wageningen_narcis_oai_library_wur_nl_wurpubs_501724
swepub_primary_oai_swepub_ki_se_506098
swepub_primary_oai_DiVA_org_uu_422330
swepub_primary_oai_DiVA_org_umu_120629
pubmedcentral_primary_oai_pubmedcentral_nih_gov_4820956
cristin_nora_10037_10368
proquest_miscellaneous_1779021486
proquest_journals_1797603946
gale_infotracmisc_A448459013
gale_infotracacademiconefile_A448459013
gale_healthsolutions_A448459013
pubmed_primary_27044418
crossref_citationtrail_10_1186_s12916_016_0607_5
crossref_primary_10_1186_s12916_016_0607_5
ProviderPackageCode CITATION
AAYXX
QVL
PublicationCentury 2000
PublicationDate 2016-04-05
PublicationDateYYYYMMDD 2016-04-05
PublicationDate_xml – month: 04
  year: 2016
  text: 2016-04-05
  day: 05
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC medicine
PublicationTitleAlternate BMC Med
PublicationYear 2016
Publisher BioMed Central Ltd
BioMed Central
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
References R Ladeiras-Lopes (607_CR8) 2008; 19
P Boffetta (607_CR20) 2014; 29
S Gandini (607_CR7) 2008; 122
N Orsini (607_CR29) 2012; 175
L Dossus (607_CR31) 2014; 134
IR White (607_CR22) 2010; 29
JL Watters (607_CR34) 2009; 18
607_CR39
R DerSimonian (607_CR25) 1986; 7
607_CR2
C Pothirat (607_CR42) 2015; 10
L Zou (607_CR9) 2014; 50
PN Lee (607_CR4) 2012; 12
S Iodice (607_CR10) 2008; 393
A Karahalios (607_CR23) 2013; 10
IT Gram (607_CR33) 2015; 182
N Hamajima (607_CR32) 2002; 87
H Poghosyan (607_CR37) 2014; 66
M Ng (607_CR1) 2014; 311
J Peto (607_CR40) 2011; 104
H Brenner (607_CR24) 1993; 4
P Gnagnarella (607_CR35) 2013; 24
S Rohrmann (607_CR13) 2013; 108
PS Liang (607_CR5) 2009; 124
U Mons (607_CR18) 2015; 350
RD Riley (607_CR14) 2010; 340
G Naik (607_CR15) 2012; 62
J Paling (607_CR16) 2003; 327
M Huncharek (607_CR12) 2010; 100
E Botteri (607_CR6) 2008; 300
S Greenland (607_CR28) 1992; 135
LA Stewart (607_CR30) 2015; 313
V Marinho (607_CR41) 2010; 26
JS Fry (607_CR38) 2013; 67
607_CR21
M Borenstein (607_CR27) 2010; 1
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (607_CR3) 2004; 83
MM Gaudet (607_CR11) 2013; 105
JP Higgins (607_CR26) 2002; 21
G Grosso (607_CR36) 2013; 13 Suppl 2
C Gellert (607_CR17) 2013; 22
A Muezzinler (607_CR19) 2015; 49
References_xml – volume: 49
  start-page: e53
  year: 2015
  ident: 607_CR19
  publication-title: Am J Prev Med
  doi: 10.1016/j.amepre.2015.04.004
– volume: 100
  start-page: 693
  year: 2010
  ident: 607_CR12
  publication-title: Am J Public Health
  doi: 10.2105/AJPH.2008.150508
– volume: 83
  start-page: 1
  year: 2004
  ident: 607_CR3
  publication-title: IARC Monogr Eval Carcinog Risks Hum
– volume: 66
  start-page: 12
  year: 2014
  ident: 607_CR37
  publication-title: Prev Med
  doi: 10.1016/j.ypmed.2014.05.013
– volume: 29
  start-page: 929
  year: 2014
  ident: 607_CR20
  publication-title: Eur J Epidemiol
  doi: 10.1007/s10654-014-9977-1
– volume: 104
  start-page: 389
  year: 2011
  ident: 607_CR40
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6606080
– volume: 300
  start-page: 2765
  year: 2008
  ident: 607_CR6
  publication-title: JAMA
  doi: 10.1001/jama.2008.839
– volume: 87
  start-page: 1234
  year: 2002
  ident: 607_CR32
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600596
– ident: 607_CR2
– volume: 10
  start-page: 6
  year: 2013
  ident: 607_CR23
  publication-title: Emerg Themes Epidemiol
  doi: 10.1186/1742-7622-10-6
– volume: 13 Suppl 2
  start-page: S14
  year: 2013
  ident: 607_CR36
  publication-title: BMC Surg
  doi: 10.1186/1471-2482-13-S2-S14
– volume: 393
  start-page: 535
  year: 2008
  ident: 607_CR10
  publication-title: Langenbecks Arch Surg
  doi: 10.1007/s00423-007-0266-2
– volume: 122
  start-page: 155
  year: 2008
  ident: 607_CR7
  publication-title: Int J Cancer
  doi: 10.1002/ijc.23033
– volume: 50
  start-page: 193
  year: 2014
  ident: 607_CR9
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.08.014
– volume: 7
  start-page: 177
  year: 1986
  ident: 607_CR25
  publication-title: Control Clin Trials
  doi: 10.1016/0197-2456(86)90046-2
– volume: 67
  start-page: 13
  year: 2013
  ident: 607_CR38
  publication-title: Regul Toxicol Pharmacol
  doi: 10.1016/j.yrtph.2013.06.001
– volume: 340
  start-page: c221
  year: 2010
  ident: 607_CR14
  publication-title: BMJ
  doi: 10.1136/bmj.c221
– ident: 607_CR39
– volume: 21
  start-page: 1539
  year: 2002
  ident: 607_CR26
  publication-title: Stat Med
  doi: 10.1002/sim.1186
– volume: 134
  start-page: 1871
  year: 2014
  ident: 607_CR31
  publication-title: Int J Cancer
  doi: 10.1002/ijc.28508
– volume: 19
  start-page: 689
  year: 2008
  ident: 607_CR8
  publication-title: Cancer Causes Control
  doi: 10.1007/s10552-008-9132-y
– volume: 62
  start-page: 213
  year: 2012
  ident: 607_CR15
  publication-title: Br J Gen Pract
  doi: 10.3399/bjgp12X636236
– volume: 327
  start-page: 745
  year: 2003
  ident: 607_CR16
  publication-title: BMJ
  doi: 10.1136/bmj.327.7417.745
– volume: 182
  start-page: 917
  year: 2015
  ident: 607_CR33
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwv092
– volume: 12
  start-page: 385
  year: 2012
  ident: 607_CR4
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-12-385
– volume: 124
  start-page: 2406
  year: 2009
  ident: 607_CR5
  publication-title: Int J Cancer
  doi: 10.1002/ijc.24191
– volume: 311
  start-page: 183
  year: 2014
  ident: 607_CR1
  publication-title: JAMA
  doi: 10.1001/jama.2013.284692
– volume: 22
  start-page: 227
  year: 2013
  ident: 607_CR17
  publication-title: Tob Control
  doi: 10.1136/tobaccocontrol-2012-050572
– volume: 1
  start-page: 97
  year: 2010
  ident: 607_CR27
  publication-title: Res Synth Methods
  doi: 10.1002/jrsm.12
– volume: 350
  start-page: h1551
  year: 2015
  ident: 607_CR18
  publication-title: BMJ
  doi: 10.1136/bmj.h1551
– ident: 607_CR21
– volume: 24
  start-page: 2606
  year: 2013
  ident: 607_CR35
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt302
– volume: 26
  start-page: 2213
  year: 2010
  ident: 607_CR41
  publication-title: Cad Saude Publica
  doi: 10.1590/S0102-311X2010001200002
– volume: 29
  start-page: 2920
  year: 2010
  ident: 607_CR22
  publication-title: Stat Med
  doi: 10.1002/sim.3944
– volume: 18
  start-page: 2427
  year: 2009
  ident: 607_CR34
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-09-0252
– volume: 10
  start-page: 725
  year: 2015
  ident: 607_CR42
  publication-title: Clin Interv Aging
  doi: 10.2147/CIA.S80506
– volume: 105
  start-page: 515
  year: 2013
  ident: 607_CR11
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djt023
– volume: 175
  start-page: 66
  year: 2012
  ident: 607_CR29
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwr265
– volume: 4
  start-page: 229
  year: 1993
  ident: 607_CR24
  publication-title: Epidemiology
  doi: 10.1097/00001648-199305000-00006
– volume: 108
  start-page: 708
  year: 2013
  ident: 607_CR13
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.520
– volume: 313
  start-page: 1657
  year: 2015
  ident: 607_CR30
  publication-title: JAMA
  doi: 10.1001/jama.2015.3656
– volume: 135
  start-page: 1301
  year: 1992
  ident: 607_CR28
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a116237
SSID ssj0025774
Score 2.5056145
SecondaryResourceType review_article
Snippet Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely clear. Rate...
Background Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely...
Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely...
Background: Smoking is the most important individual risk factor for many cancer sites but its association with breast and prostate cancer is not entirely...
SourceID wageningen
swepub
pubmedcentral
cristin
proquest
gale
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 62
SubjectTerms Age
Aging
Breast Neoplasms - epidemiology
Breast Neoplasms - prevention & control
Cancer
Care and treatment
Cohort
Cohort Studies
Community medicine, Social medicine: 801
Complications and side effects
Confidence intervals
Consortia
Development and progression
Exercise
Female
Health aspects
Health sciences: 800
Helsefag: 800
Humans
Incidence
Lung cancer
Lung Neoplasms - epidemiology
Lung Neoplasms - prevention & control
Male
Medical disciplines: 700
Medisinske Fag: 700
Meta-analysis
Mortality
Netherlands
Proportional Hazards Models
Prospective Studies
Prostate cancer
Prostatic Neoplasms - epidemiology
Prostatic Neoplasms - prevention & control
Risk Factors
Samfunnsmedisin, sosialmedisin: 801
Smoking
Smoking - epidemiology
Smoking - therapy
Smoking cessation
Smoking Cessation - statistics & numerical data
VDP
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSGg8ID63wAAj8SEhWUtrx054QdVgqpCGhGCob1YSO1CxOqVptD-Jf5M7x02XCfWhbeSckya-O9_Zd78j5FUlZWbAMGZ2nFZMiEoyRF1j0hYgloVJCl-t4eyLnJ6Lz7NkFhbcmhBWudGJXlGbusQ18mNgHCVjngn5YfmHYdUo3F0NJTRuklsIXYYhXWq2dbgSsG3CTuYolccNzG0j9J_hI2PFMIOp9KLkBrPSdd18ZXK6HjgZ4EXvkP1LEH_n86GuzE-n98jdYFjSSccJ98kN6x6Q22dh6_wh-fu1zbvAID8WtK4o2H60WdS4WM7yMEzW0BIZYUUx6JziMi1FNAkaggVwMZEiOnJtmvd0Ydc5ywOuCV5y3ud30WUeIrahA8ahUsxkoViQd7VuNrc_mWJxnG_Q7Bpon7eLR-T89NP3kykLVRpYCQ7umoGFl-cg5WkMpksGc64FI0rFsZFZxY3Ix8pwWaRFmXAEBjJVwYERDHh6Ik6zMuOPyZ6rnT0kdFSogpdgUxU2E4qbPDGpzaWxiiuTljYih2G8tAMBQbxlruCbyzQi8WYAdRnQzbHIxoX2Xk4qdTf6GiPacPR1EpF3fZdlB-2xi_gFcoXuslN7taAn4N4KzN_lEXnrKVAxwJ3LPOQ3wKMhxNaA8mhACQJdDk9vOE8HhdLoLftH5GV_GntikJyzdYs0KkMIvBRoDjpG7R9srBAYcATvSQ1YuCdAmPHhGTf_5eHGBRiJ4EVH5E3H7IMuH-c_Jrpe_dTtAlHJYznOIvJ6J2GrBdikPP7_BUPTbziyGtEvM_jPfCtd2mGNrcbThoVOfdmutLvAH-jaQC-wysWT3a_xKdkfe00gWJwckb31qrXPwL5cF8-9EvkH7IR_EA
  priority: 102
  providerName: ProQuest
Title Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium
URI https://www.ncbi.nlm.nih.gov/pubmed/27044418
https://www.proquest.com/docview/1797603946
https://www.proquest.com/docview/1779021486
http://hdl.handle.net/10037/10368
https://pubmed.ncbi.nlm.nih.gov/PMC4820956
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-120629
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422330
http://kipublications.ki.se/Default.aspx?queryparsed=id:133289525
http://www.narcis.nl/publication/RecordID/oai:library.wur.nl:wurpubs%2F501724
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1tb9MwELb2ItD4gHhfYBQj8SIhBbLasRMkhLqxqULqBIOiii9WEjtQ0SYjaTT4RfxN7hInLNPYh6ZVcpc08XP2nXN-jpAnqRChBsfYNcMgdTlPhYusa64wMZhlrP24rtYwORLjKX8_82drpC1vZR9geWFoh_WkpsXi5a-fv9-Cwb-pDT4Qr0oYs3YxLoaP8KTrr5NNGJgk2umEdy8VAJyS2xebF6ohMbBE_jSsAHIlqY0s641X53vtM8PW-ZRKSzx6jWydQseQ1SulzoxchzfIdety0lGDkZtkzWS3yNWJfal-m_z5WEVNylDdSjRPKXiFtFzmOI3uRrYBjaYJQqSgmI5OcQKXIs8EtWkEOM1IkTc51-VrujSryI0s4wmect6t_KInkc3lBgXMUKW4xoViqd5iVbaX3x9j2ZxPsDsrYf-8Wt4h08ODz_tj19ZvcBMIfVcu-H5RBPYfeODUhDAaG3CvpOdpEaZM82goNRNxECc-Q8ogncYMIKIhBuReECYhu0s2sjwz24TuxjJmCXhbsQm5ZDrydWAioY1kUgeJcci2bS-VgekgEzOTsGUicIjXNqBKLO85lt9YqDr-CYRqgKAw1w2BoHyHvOhUThrSj8uEHyEqVLNutesw1AgCX44re5lDntcSCGK4chLZlQ9wa0i-1ZPc6UmCqSf9wy3yVGspCnpUKTwWcuGQx91h1MT0uczkFcrIEMnxApC51wC1u7EW8g6RPQh3AkhA3j-Szb_XROQc3EeIrx3yrAF7T-Xd_MtI5cU3VS2Rr9wTw9AhTy8VrBQHb5V5F5_Q7voBv4xCXswQ_jP7Z10qw-pbZS1rp0DVaVWobIFfoFqCFvjr_P5_n8EDsjWs-wPuev4O2VgVlXkITucqHpB1OZMDsrl3cPTheFBP3Qzq7gW2x3tf_wLI0oZF
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF5VrQTlAXHXUOgiUZCQrDre9dpGQij0UEqbiKNFfVts7xoiGjvEsSJ-EW_8RmbstVtXKG99yCF71tfMzrGe-YaQF6kQoQLH2NZukNqcp8JG1DVb6BimZay8uOrWMByJwSn_cOadrZC_TS0MplU2OrFS1CpPcI18BwTHFw4LuXg3_WVj1yh8u9q00KjF4kj_XkDIVrw93AP-brvuwf7J7sA2XQXsBAKyuQ0eSRSBVAYOmNoQbIQGo-87jhJhyhSPXF8xEQdx4jEEslFpzODCFUQm3AnCBMGXQOWvcQahzCpZe78_-vi5DfE88KbMu9NeIHYKsKY9jNjhAyexsWYqqSZv1rGDV63BJXN4NVXTAJreIusLUDhZVYF1ySIe3CG3jStL-7Xs3SUrOrtHbgzNy_r75M-nMqpTkSru0zyl4G3SYpLj8rwdGcHQiiYoejOKae4UF4Yp4ldQk56Ay5cU8ZhzVbyhEz2P7MggqeAhx21FGZ1GJkccBmDmK8XaGYotgGfzojn97gDb8XyBzVkB28fl5AE5vRYOPiSrWZ7pDUJ7sR-zBLy4WIfcZyryVKAjobTPfBUk2iIbhl8ygymJCM_Mh28mAos4DQNlYvDUsa3HuaziqkDImvsSc-iQ-9KzyOt2yLQGE1lGvIVSIet62FYRyT4E1BwrhplFXlUUqIrgzElkKirg1hDUq0O52aEEFZJ0dzeSJ40KK-TFhLPI83Y3jsS0vEznJdL4IYLuBUDzqBbU9sZcH6EIe_Cc_I4ItwQIbN7dk41_VADnHNxSiNst8rIW9s6QvfHXvsxn32U5QRx0R7ihRbaXEpaSgxfMnP8f0Gz6Cf-0RLzNEK6ZXcwumWFXr6KiNUurclHOZHaOPzC0gFEQB_DHyx_jFrk5OBkey-PD0dETsu5WWoHbjrdJVuezUj8F73YePzMqhZJv163F_gG-jrwj
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantification+of+the+smoking-associated+cancer+risk+with+rate+advancement+periods%3A+meta-analysis+of+individual+participant+data+from+cohorts+of+the+CHANCES+consortium&rft.jtitle=BMC+medicine&rft.au=Ord%C3%B3%C3%B1ez-Mena%2C+Jos%C3%A9+Manuel&rft.au=Sch%C3%B6ttker%2C+Ben&rft.au=Mons%2C+Ute&rft.au=Jenab%2C+Mazda&rft.date=2016-04-05&rft.eissn=1741-7015&rft.volume=14&rft.spage=62&rft_id=info:doi/10.1186%2Fs12916-016-0607-5&rft_id=info%3Apmid%2F27044418&rft.externalDocID=27044418
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1741-7015&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1741-7015&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1741-7015&client=summon